文献速递肾癌与肾肿瘤

法国与挪威结节性硬化症患者肾血管平滑肌脂肪瘤患病率及自发性出血相关问卷调查

Prevalence of Renal Angiomyolipomas and Spontaneous Bleeding Related to Angiomyolipomas in Tuberous Sclerosis Complex Patients in France and Norway-a Questionnaire Study.
PubMed 文献 · Urology · 2017-02-21

该问卷调查研究纳入法国257例和挪威100例结节性硬化症患者,评估肾血管平滑肌脂肪瘤(AML)患病率及AML相关出血情况。189例(54%)报告患有AML,25例(7%)报告曾出血,首次出血年龄27.6±8.5岁,68%首次出血发生在20至30岁。总体无出血生存率在72岁时为81%(95%CI 68-89),AML患者为66%(95%CI 43-82),法国与挪威无出血生存相似(P=.471)。

要点

  • 357例结节性硬化症患者中189例(54%)报告患有肾血管平滑肌脂肪瘤(AML)。
  • 25例(7%)报告曾发生AML相关出血,68%首次出血发生在20至30岁。
  • AML患者72岁时无出血生存率为66%(95%CI 43-82)。

核心结论

  • 54%的患者报告患有AML,7%(25/357)报告出血。
  • 68%的首次出血发生在20至30岁。
  • 出血患者中38%接受保守治疗,62%需要积极治疗。

研究设计与样本

  • 问卷调查研究,由法国结节性硬化症参考中心设计并通过大学医院和患者协会发放(2009-2011年),随后发放给挪威国家罕见癫痫相关疾病中心登记的患者(2013-2014年)。
  • 共纳入357例患者(法国257例,挪威100例)。

主要发现

  • 189例(54%)报告患有AML,111例(32%)报告无AML,50例(14%)报告不知是否患有AML。
  • 25例(法国19例,挪威6例)报告曾出血,首次出血年龄(22例已知)为27.6±8.5岁。
  • 15例(法国11例,挪威4例)首次出血发生在20至30岁。
  • 法国与挪威无出血生存相似(P=.471)。
  • 总体人群72岁时无出血生存率为81%(95%CI 68-89),AML患者为66%(95%CI 43-82)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the prevalence of renal angiomyolipomas (AMLs) and AML-related bleedings among patients with tuberous sclerosis complex and to gather information about associated treatments. METHODS: A questionnaire survey was undertaken by the French Reference Centre for Tuberous Sclerosis Complex and distributed through university hospitals and the patients' association (2009-2011). The questionnaire was then distributed to patients registered by the Norwegian National Centre for Rare Epilepsy-Related Disorders (2013-2014). Risk of bleeding was estimated by Kaplan-Meier analysis. RESULTS: We included 357 patients (France, n = 257; Norway, n = 100); 189 (54%) reported having AMLs, 111 (32%) reported not having AMLs, and 50 (14%) reported not knowing whether they had AMLs. Twenty-five patients (France, n = 19; Norway, n = 6) reported that they have had bleeding. Age at first bleeding (known in 22 patients) was 27.6 ± 8.5 years. Fifteen patients (France, n = 11; Norway, n = 4) experienced first bleeding between 20 and 30 years. Bleeding-free survival was similar in France and Norway (P = .471). The bleeding-free survival rate at 72 years was 81% (95% confidence interval: 68-89) in the overall population and 66% (95% confidence interval: 43-82) in patients with AMLs. Bleeding treatment (known in 24 patients) consisted of conservative measures (n = 9), embolization (n = 8), nephrectomy (n = 4), embolization and nephrectomy (n = 2), or partial nephrectomy (n = 1). Fifteen French patients reported prophylactic treatment. In Norway, this information was known only in patients with renal bleeding and was reported in two. CONCLUSION: Fifty-four percent of the patients reported having AMLs and 7% (25/357) reported bleeding. Sixty-eight percent of first bleedings occurred between 20 and 30 years. Bleedings were managed conservatively in 38% of the patients and 62% needed active treatment.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Cockerell I, Guenin M, Heimdal K, et al. Prevalence of Renal Angiomyolipomas and Spontaneous Bleeding Related to Angiomyolipomas in Tuberous Sclerosis Complex Patients in France and Norway-a Questionnaire Study. Urology. 2017. PMID: 28232177. doi:10.1016/j.urology.2017.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。